Influence of Prostate Size and PI-RADS on PSA Density Thresholds for Biopsy

Overview

This study evaluated the risk of clinically significant prostate cancer (csPCa) across PSA density (PSAd) values within each PI-RADS category to identify optimal biopsy thresholds. It also assessed how prostate volume impacts PSAd's predictive performance, aiming to refine biopsy decision-making and reduce unnecessary procedures.

Background

Multiparametric MRI (mpMRI) is established in prostate cancer diagnosis, improving detection of csPCa and reducing unnecessary biopsies. Despite high negative predictive value, mpMRI has limited positive predictive value, especially for PI-RADS 3 lesions, leading to many unnecessary biopsies. PSA density (PSAd) is a promising biomarker to augment biopsy decisions, but the optimal PSAd cutoff remains unclear, particularly across different PI-RADS categories and prostate volumes. This study addresses these gaps by analyzing PSAd thresholds and prostate size effects on biopsy decision-making.

Data Highlights

A total of 2190 patients were included after exclusions. csPCa was defined as ISUP Grade Group ≥ 2. The study analyzed PSAd values across PI-RADS categories 1–5, correlating with biopsy outcomes. Patients with low-risk PI-RADS 1–3 and no progression after 12 months were included in the clinically insignificant group. The study used MRI-guided fusion and systematic biopsies as reference standards.

Key Findings

• mpMRI has high negative predictive value but limited positive predictive value, especially in PI-RADS 3 lesions, with csPCa detection rates of 12–18.5%.
• PSAd threshold of 0.15 ng/mL² is commonly used but was originally established pre-MRI era and may not be optimal across all PI-RADS categories.
• Prostate volume influences PSA and PSAd values, affecting their predictive accuracy for csPCa.
• Quantitative analysis across the full PSAd range within each PI-RADS category is necessary to identify safe biopsy deferral thresholds based on a 10% csPCa risk.
• Excluding patients with prostatitis, prior interventions, or poor MRI quality ensured a robust cohort for analysis.
• Expert uroradiologists interpreted mpMRI using PI-RADS v2 and v2.1, ensuring standardized lesion assessment.

Clinical Implications

Clinicians should consider adjusting PSAd biopsy thresholds according to PI-RADS category and prostate volume to better stratify csPCa risk and avoid unnecessary biopsies. Reliance on a fixed PSAd cutoff of 0.15 ng/mL² may lead to overdiagnosis or missed significant cancers, particularly in patients with larger prostate volumes or equivocal MRI findings. Integrating mpMRI findings with individualized PSAd thresholds can optimize patient management.

Conclusion

This study highlights the need for tailored PSAd thresholds based on PI-RADS classification and prostate size to improve biopsy decision-making. Such an approach may enhance detection of clinically significant prostate cancer while minimizing unnecessary invasive procedures.

References

1. Karanasios et al 2024 -- Influence of Prostate Size and PI-RADS Classification on PSA Density Thresholds for Biopsy Decision-Making